The Pharma Data

NOVEMBER 3, 2020

acted as sole book-running manager for the offering. Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies.

Pharmaceuticals 52

Pharmaceuticals Therapies Production 52

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

SEPTEMBER 7, 2020

If your anxiety persists, there are lots of self-help books on the best therapies, such as cognitive behavioural therapy (CBT), which is also provided on the NHS. CBT is a talking therapy which helps people deal with overwhelming problems by breaking them down into smaller chunks.

Virus 52

Virus Therapies Treatment Science 52

The Pharma Data

NOVEMBER 29, 2020

Dr. Palmer has authored over 100 publications, abstracts, articles, and book chapters, in addition to a best-selling book on liver disease “Dr. Ascletis has three marketed products and thirteen R&D pipeline drug candidates or combination therapies (nine of them developed in-house).

Clinical Development 40

Clinical Development Disease Clinical Trials Therapies 40

LifeSciVC

AUGUST 21, 2024

Regulatory Submissions, Meetings and Feedback How is the Briefing Book coming? The average time from submitting a meeting request to FDA and being granted a meeting date has recently accelerated so Briefing Books should be in final form before submitting the meeting request. It is keeping patients front and center.

Clinical Trials 77

Clinical Trials Trials Disease Treatment 77

The Open Targets Blog

SEPTEMBER 21, 2023

Open Targets’s work will help drug discovery scientists gain a more in-depth understanding of the diseases they are developing therapies for, the most promising targets to pursue, and hopefully, via improving success rates, reduce the cost and time to develop new medicines. What are some of the challenges of your new role?

Organic Chemistry 82

Organic Chemistry Process Chemistry Small Molecule Science 82

The Pharma Data

DECEMBER 3, 2020

Indeed, shortly after her family relocated to California when she was 14, she signed with an independent record label and began booking gigs. As an outpatient, she continued physical, speech and occupational therapy. After she was released a month later, she did about two months of intensive therapy. THURSDAY, Dec.

Doctors 52

Doctors Hospitals Therapies 52

The Pharma Data

DECEMBER 8, 2020

Citigroup, Evercore ISI and Mizuho Securities are acting as joint book-running managers for the offering. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.

Marketing 52

Marketing Disease Therapies 52

The Pharma Data

OCTOBER 27, 2020

are acting as joint book-running managers in the offering. are also acting as book-running managers in the offering. Goldman Sachs & Co. LLC, SVB Leerink LLC, Cowen and Company, LLC and Evercore Group, L.L.C. Barclays Capital Inc., Credit Suisse Securities ( USA ) LLC and Piper Sandler & Co. Forward-Looking Statements.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

JANUARY 14, 2021

is acting as sole book-running manager for the offering. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. ThinkEquity, a division of Fordham Financial Management, Inc.,

Small Molecule 52

Small Molecule Therapies Drug Development Drugs 52

The Pharma Data

DECEMBER 8, 2020

(“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of 5,434,783 shares of its common stock at a price to the public of $23.00

Pharmaceuticals 52

Pharmaceuticals Therapies Marketing 52

The Pharma Data

JANUARY 7, 2021

a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 CAMBRIDGE, Mass.,

Therapies 40

Therapies Marketing 40

Vial

FEBRUARY 19, 2024

Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. Can you elaborate on how the platform allows your company to tailor therapy? Ahmed Hamdy: Absolutely.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

Olympian Clinical Research

SEPTEMBER 7, 2021

Cognitive behavioral therapy can be helpful in managing thoughts, identifying behaviors, and understanding why you are having these impulses in the first place. Find ways to distract yourself from intrusive thoughts by going for a walk or reading a book. Contact Olympian Clinical Research .

Clinical Trials 52

Clinical Trials Clinical Research Trials Compliance 52

The Pharma Data

DECEMBER 9, 2020

is acting as the sole book-running manager for the offering. About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. SAN DIEGO, Dec. Wainwright & Co.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

The Pharma Data

JANUARY 7, 2021

and Wells Fargo Securities are acting as joint book-running managers for the offering. SUZHOU and SHANGHAI, China , Jan. 8, 2021 /PRNewswire/ — Gracell Biotechnologies Inc. Citigroup, Jefferies, Piper Sandler & Co. A copy of the prospectus relating to the offering may be obtained by contacting: Citigroup Global Markets Inc.,

Therapies 40

Therapies Marketing Production Treatment 40

The Pharma Data

OCTOBER 23, 2020

Elmaleh holds more than 140 patents and applications for drugs and molecular imaging agents, several of which are in late-stage clinical trials for Neurodegenerative diseases treatment such Alzheimer’s and ALS and for diagnosis of atherosclerosis and the monitoring of vascular drug therapies.

Organic Chemistry 52

Organic Chemistry Clinical Trials Science Pharmaceuticals 52

The Pharma Data

DECEMBER 16, 2020

Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares. and JMP Securities LLC are acting as joint book-running managers for this offering. Piper Sandler & Co., Evercore Group L.L.C.

Therapies 40

Therapies Clinical Development Disease Marketing 40

The Pharma Data

OCTOBER 15, 2020

NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00

Therapies 40

Therapies Marketing 40

NIH Director's Blog: Drug Discovery

MAY 9, 2019

Similarly, when the complete human genome sequence was revealed for the first time in 2003, commentators (including me) referred to this as the moment where the book of life for humans was revealed. When NIH’s Marshall Nirenberg and his colleagues cracked the genetic code in 1961, it was called the solution to life’s greatest secret.

Engineering 52

Engineering Regulations Science Therapies 52

The Pharma Data

DECEMBER 1, 2020

Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 10,256,411 shares of its common stock, offered at a public offering price of $9.75 are acting as joint book-running managers for the offering.

Therapies 52

Therapies Disease Production Marketing 52

The Pharma Data

OCTOBER 15, 2020

Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Aligos’ common stock is expected to begin trading on the Nasdaq Global Select Market on October 16, 2020, under the ticker symbol “ALGS.” The offering is expected to close on October 20, 2020, subject to customary closing conditions.

Disease 40

Disease Drug Development Therapies Treatment 40

The Pharma Data

JANUARY 19, 2021

is acting as the sole book-running manager for the offering. The Company’s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation. Wainwright & Co.

Clinical Trials 52

Clinical Trials Trials Clinical Development Pharmaceutical Companies 52

Elrig

SEPTEMBER 19, 2023

Drug Discovery 2023: A broad and inclusive event Drug Discovery 2023 focuses on bringing new therapies from the lab to the patient, using new tools across ‘omics, personalized medicine, and chemistry. There are many more hotels available, both in the city centre and a short drive out, on alternative accommodation booking sites.

Drugs 59

Drugs Disease Therapies Research 59

KIF1A

APRIL 24, 2023

If you are attending in person please fill out our conference registration form and hotel room booking form. – FDA: The United States Food and Drug Administration has announced its approval of the use of biomarkers in the assessment of gene therapies. It’s time to sign up for the conference and reserve your hotel rooms!

Packaging 52

Packaging Drug Development Therapies Research 52

The Pharma Data

OCTOBER 14, 2020

Pre-clinical and clinical proof-of-concept data from a first-in-human single dose DSR study demonstrated that single dose DSR therapy was safe and well-tolerated and the positive results were published in the high impact peer-reviewed cardiovascular journal, Circulation.

Clinical Trials 40

Clinical Trials Therapies Clinical Research Trials 40

The Pharma Data

JANUARY 13, 2021

Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of $9.50

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

The Pharma Data

DECEMBER 15, 2020

Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50 About Ocular Therapeutix, Inc.

FDA Approval 40

FDA Approval Disease Therapies Clinical Development 40

Drug Target Review

FEBRUARY 13, 2024

The second thing was a book on thalidomide and its discovery, which I found fascinating and inspired me to pursue a career in drug discovery. I started my career in the early stages of the targeted approach to drug therapies.

International 59

International Science Drugs Engineering 59

The Pharma Data

DECEMBER 14, 2020

Morgan, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Wainwright & Co. is acting as lead manager for the offering.

Pharmaceuticals 40

Pharmaceuticals Treatment Marketing Therapies 40

The Pharma Data

DECEMBER 14, 2020

are acting as joint book-running managers for the proposed offering. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C., and Cantor Fitzgerald & Co. Riley Securities, Inc.,

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

Perficient: Drug Development

NOVEMBER 7, 2023

But, occasionally, you’ll want to motivate users to fill out a form, download an e-book, sign up for a seminar or any number of other related activities. Make it easy for them to verify your claims no matter how they’re interacting with you. Of course, most of your conversion activities should be geared toward shopping for a health plan.

Therapies 52

Therapies Treatment Production Research 52

The Pharma Data

JANUARY 7, 2021

Jefferies is acting as the sole book-running manager for the offering and Oppenheimer & Co. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. is acting as lead manager for the offering.

Clinical Development 52

Clinical Development Disease Treatment FDA Approval 52

The Pharma Data

OCTOBER 21, 2020

Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the pricing of its public offering of 4,687,500 shares of its common stock at a public offering price of $40.00 are acting as joint book-running managers for the offering. BOSTON, Oct.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

The Pharma Data

DECEMBER 15, 2020

are acting as joint book-running managers for the offering. Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.

Targeted Protein Degradation 40

Targeted Protein Degradation Engineering Clinical Trials Disease 40

Drug Target Review

FEBRUARY 14, 2025

He has published several papers and two books and has twelve issued patents. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997.

Drugs 52

Drugs Research Immune Response Science 52

The Pharma Data

DECEMBER 2, 2020

and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering of common stock. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. Piper Sandler & Co.

Production 40

Production Drug Development Therapies Research 40